Leavey S F, Walshe J J, O'Neill D, Atkins N, Donohoe J, Hickey D, Carmody M
Department of Nephrology, Beaumont Hospital, Dublin, Ireland.
Ir J Med Sci. 1997 Oct-Dec;166(4):245-8. doi: 10.1007/BF02944244.
The importance of certain positive crossmatches (CM+) in kidney transplantation remains controversial. Fifty consecutive kidney transplants were performed across a CM+ between Jan. 1990-April 1994. In 19 cases there was an isolated B-cell CM+ (Group I), in 24 an historic T-cell IgM CM+ (Group II) and in 7 an historic T-cell IgG CM+ (Group III). Comparing groups I:II:III: early acute rejection affected 32%, 42%, 57% of grafts; mean serum creatinine at 3 months was 166, 150, 229 umol/l (p < 0.05); 1 yr graft survival was 95 per cent, 96 per cent, 71 per cent (p = 0.09). In group III both graft losses were in the setting of an additional current B-cell CM+.
Transplantation performed in either the presence of an isolated B-cell CM+ or in the presence of an historic T-cell IgM CM+ was associated with acceptable outcomes at 1 yr. An historic T-cell IgG CM+ was confirmed as a contraindication to transplantation in most circumstances, especially when coupled with a current B-cell CM+.
肾移植中某些阳性交叉配型(CM+)的重要性仍存在争议。1990年1月至1994年4月期间,连续进行了50例跨越CM+的肾移植。其中19例为单纯B细胞CM+(第一组),24例为既往T细胞IgM CM+(第二组),7例为既往T细胞IgG CM+(第三组)。比较第一组、第二组和第三组:早期急性排斥反应分别影响32%、42%、57%的移植物;3个月时的平均血清肌酐分别为166、150、229 μmol/L(p<0.05);1年移植物存活率分别为95%、96%、71%(p=0.09)。在第三组中,两次移植物丢失均发生在同时存在当前B细胞CM+的情况下。
在单纯B细胞CM+或既往T细胞IgM CM+存在的情况下进行移植,1年时的结果可接受。既往T细胞IgG CM+在大多数情况下被确认为移植禁忌证,尤其是与当前B细胞CM+同时存在时。